Moreover, protein expression levels of PRMT5 and HSP90 were unchanged in ATL and T-ALL cell lines after treatment with PRMT5 inhibitor; however, HLCL61 treatment markedly reduced both AKT and NEMO expression, which are known client proteins of HSP90 in a dose-dependent manner. This evidence concerns the gene PRMT5 and acute lymphoblastic leukemia.